We have observed
8 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 publication dated after
December 16, 2012).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
MUTANT BACTERIA FOR PRODUCTION OF GENERALIZED MODULES FOR MEMBRANE ANTIGENS
ANALYSIS OF SACCHARIDE VACCINES WITHOUT INTERFERENCE
LIPOSOMES WITH LIPIDS HAVING AN ADVANTAGEOUS PKA-VALUE FOR RNA DELIVERY
SALMONELLA CONJUGATE VACCINES
PREVENTION OF STAPHYLOCOCCUS AUREUS INFECTIONS BY GLYCOPROTEIN VACCINES SYNTHESIZED IN ESCHERICHIA COLI
MUTANT STAPHYLOCOCCAL ANTIGENS
PURIFICATION OF STAPHYLOCOCCUS AUREUS TYPE 5 AND TYPE 8 CAPSULAR SACCHARIDES
METHOD OF TREATMENT